CN119095868A - 面部肌张力障碍的治疗 - Google Patents

面部肌张力障碍的治疗 Download PDF

Info

Publication number
CN119095868A
CN119095868A CN202380036925.9A CN202380036925A CN119095868A CN 119095868 A CN119095868 A CN 119095868A CN 202380036925 A CN202380036925 A CN 202380036925A CN 119095868 A CN119095868 A CN 119095868A
Authority
CN
China
Prior art keywords
unit dose
muscle
administering
modified bont
orbicularis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202380036925.9A
Other languages
English (en)
Chinese (zh)
Inventor
L·庞斯
N·格里戈尔
F·A·乔杜里
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ipsen Biopharm Ltd
Original Assignee
Ipsen Biopharm Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ipsen Biopharm Ltd filed Critical Ipsen Biopharm Ltd
Publication of CN119095868A publication Critical patent/CN119095868A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24069—Bontoxilysin (3.4.24.69), i.e. botulinum neurotoxin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
CN202380036925.9A 2022-04-29 2023-03-23 面部肌张力障碍的治疗 Pending CN119095868A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB2206361.4A GB202206361D0 (en) 2022-04-29 2022-04-29 Treatment of a facial dystonia
GB2206361.4 2022-04-29
PCT/GB2023/050746 WO2023209327A1 (en) 2022-04-29 2023-03-23 Bont/a for use in treating a facial dystonia

Publications (1)

Publication Number Publication Date
CN119095868A true CN119095868A (zh) 2024-12-06

Family

ID=81943823

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202380036925.9A Pending CN119095868A (zh) 2022-04-29 2023-03-23 面部肌张力障碍的治疗

Country Status (9)

Country Link
US (1) US20250213662A1 (https=)
EP (1) EP4514824A1 (https=)
JP (1) JP2025515346A (https=)
KR (1) KR20250004870A (https=)
CN (1) CN119095868A (https=)
AU (1) AU2023262229A1 (https=)
CA (1) CA3245925A1 (https=)
GB (1) GB202206361D0 (https=)
WO (1) WO2023209327A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025093844A1 (en) * 2023-11-01 2025-05-08 Ipsen Biopharm Limited Use of chimeric botulinum toxin a for treating blepharospasm and hemifacial spasm

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
IL99552A0 (en) 1990-09-28 1992-08-18 Ixsys Inc Compositions containing procaryotic cells,a kit for the preparation of vectors useful for the coexpression of two or more dna sequences and methods for the use thereof
DE102004043009A1 (de) 2004-09-06 2006-03-23 Toxogen Gmbh Transportprotein zum Einbringen chemischer Verbindungen in Nervenzellen
DE102005019302A1 (de) 2005-04-26 2006-11-16 Toxogen Gmbh Carrier zum Targeting von Nervenzellen
ES2369558T3 (es) 2005-09-19 2011-12-01 Allergan, Inc. Toxinas clostridiales y toxinas clostridiales activables.
CA2758274C (en) 2009-04-14 2018-04-10 Mcw Research Foundation, Inc. Engineered botulinum neurotoxin
US8853360B2 (en) 2010-06-23 2014-10-07 Wisconsin Alumni Research Foundation Engineered botulinum neurotoxin C1 with selective substrate specificity
EP3162894B1 (en) 2011-05-19 2024-01-10 Ipsen Bioinnovation Limited Methods for the manufacture of proteolytically processed polypeptides
SG10201606666XA (en) 2012-05-30 2016-09-29 Harvard College Engineered Botulinum Neurotoxin
WO2014079495A1 (en) 2012-11-21 2014-05-30 Syntaxin Limited Methods for the manufacture of proteolytically processed polypeptides
PT3274364T (pt) 2015-03-26 2021-11-05 Harvard College Neurotoxina botulínica manipulada
GB201607901D0 (en) 2016-05-05 2016-06-22 Ipsen Biopharm Ltd Chimeric neurotoxins
EP3481852B1 (en) 2016-07-08 2022-12-07 Children's Medical Center Corporation A novel botulinum neurotoxin and its derivatives
GB202003813D0 (en) * 2020-03-16 2020-04-29 Ipsen Biopharm Ltd Treatment of upper facial lines
KR20240067100A (ko) * 2021-09-23 2024-05-16 입센 바이오팜 리미티드 대상체의 안검 근육에 이환된 장애의 치료에 사용하기 위한 변형된 bont/a

Also Published As

Publication number Publication date
GB202206361D0 (en) 2022-06-15
JP2025515346A (ja) 2025-05-14
WO2023209327A1 (en) 2023-11-02
AU2023262229A1 (en) 2024-10-10
KR20250004870A (ko) 2025-01-08
EP4514824A1 (en) 2025-03-05
US20250213662A1 (en) 2025-07-03
CA3245925A1 (en) 2023-11-02

Similar Documents

Publication Publication Date Title
EP4120997A1 (en) Treatment of upper facial lines
EP4401759B1 (en) Modified bont/a for use in the treatment of cervical dystonia
US20250179461A1 (en) Modified Bont/A for Use in the Treatment of a Disorder Affecting an Eyelid Muscle of a Subject
AU2020357905B2 (en) Non-toxic clostridial neurotoxin polypeptides for use in treating neurological disorders
CN119095868A (zh) 面部肌张力障碍的治疗
US20250302928A1 (en) Treatment of cervical dystonia
US20250177278A1 (en) Treatment of upper facial lines
WO2025093844A1 (en) Use of chimeric botulinum toxin a for treating blepharospasm and hemifacial spasm
WO2025093845A1 (en) Use of high dose chimeric botulinum toxin a for the treatment of upper facial lines
CN117979988A (zh) 用于治疗影响受试者眼睑肌肉的疾病的修饰的BoNT/A
AU2023260765A1 (en) Treatment of limb spasticity
HK40110371A (zh) 用於治疗影响受试者眼睑肌肉的疾病的修饰的bont/a
HK40118896A (zh) 上面部纹的治疗

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination